ReviewPediatric clinics of North America2012
Pharmacologic management of the opioid neonatal abstinence syndrome.
Review in Pediatric clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Sedatives for opioid withdrawal in newborn infants.The Cochrane database of systematic reviews · 2021Pooled it
- Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.The Journal of pediatrics · 2015Trial
- Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial.BMC pediatrics · 2015Trial
- The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment.Neuropharmacology · 2024Article
- Review
- Postnatal oxytocin treatment improves survival and neurodevelopmental outcomes in an animal model of neonatal abstinence syndrome.Comprehensive psychoneuroendocrinology · 2022Article
- Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.Pharmaceutics · 2022Article
- Comparison of Two Morphine Dosing Strategies in the Management of Neonatal Abstinence Syndrome.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.Clinical and translational science · 2021Review
- Transcutaneous Auricular Neurostimulation (tAN): A Novel Adjuvant Treatment in Neonatal Opioid Withdrawal Syndrome.Frontiers in human neuroscience · 2021Article
- Salivary cortisol levels as a biomarker for severity of withdrawal in opioid-exposed newborns.Pediatric research · 2020Observational
- Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic.Expert opinion on drug metabolism & toxicology · 2020Review
- Stories of Loss: Separation of Children and Mothers Who Use Opioids.Journal of ethnographic and qualitative research · 2020Article
- Methadone dosing strategies in preterm neonates can be simplified.British journal of clinical pharmacology · 2019Article
- Neonatal abstinence syndrome.Nature reviews. Disease primers · 2018Review
- The Impact of Breastfeeding on Health Outcomes for Infants Diagnosed with Neonatal Abstinence Syndrome: A Review.Cureus · 2018Review
- Update of the Scientific Opinion on opium alkaloids in poppy seeds.EFSA journal. European Food Safety Authority · 2018Article
- Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.Drug safety · 2016Review
- Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.Pharmacotherapy · 2015Article
- Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011.Journal of perinatology : official journal of the California Perinatal Association · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Opioid use in pregnant women has increased over the last decade. Following birth, infants with in utero exposure demonstrate signs and symptoms of withdrawal known as the neonatal abstinence syndrome (NAS). Infants express a spectrum of disease, with most requiring the administration of pharmacologic therapy to ensure proper growth and development. Treatment often involves prolonged hospitalization. There is a general lack of high-quality clinical trial data to guide optimal therapy, and significant heterogeneity in treatment approaches. Emerging trends in the treatment of infants with NAS include the use of sublingual buprenorphine, transition to outpatient therapy, and pharmacogenetic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.